Exact Therapeutics AS

Exact Therapeutics AS

Health CarePharmaceuticals and Biotechnology
  • Price (NOK)11.00
  • Today's Change-0.300 / -2.65%
  • Shares traded1.58k
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Jun 05 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.

  • Revenue in NOK (TTM)0.00
  • Net income in NOK-40.10m
  • Incorporated2012
  • Employees8.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Biovica International AB3.94m-93.35m275.20m33.00--1.80--69.80-2.81-2.810.11693.820.0216-1.678.55155,160.00-51.17-30.85-55.61-33.47152.10332.81-2,367.83-1,470.098.35-543.410.0592---1.5426.47-51.97------
SenzaGen AB42.45m-25.32m276.39m16.00--3.05--6.51-1.03-1.031.733.710.32924.244.56---19.63-25.18-24.68-27.9565.4478.89-59.64-214.331.86--0.0133--170.85105.0320.53---29.85--
Arctic Bioscience AS34.27m-34.02m279.07m----0.9334--8.14-1.40-1.401.4111.790.10240.70723.24---10.17---11.20--33.98---99.28--4.03--0.00--59.29--20.09------
Opticept Technologies AB11.65m-107.99m314.99m----0.818--27.03-5.26-5.260.513412.690.02730.59372.14---25.20-44.86-27.03-49.01-6.0642.23-922.44-863.201.45-11.150.0593--136.46122.77-112.89--35.79--
Corline Biomedical AB28.33m4.27m327.64m8.0076.763.3775.5511.560.19540.19541.304.450.2778--9.88--4.18-7.764.49-8.5899.92151.1415.07-76.39----0.00--233.47105.79133.65--12.38--
Exact Therapeutics AS0.00-40.10m329.97m8.00--5.07-----1.34-1.340.002.17-----------28.38---32.26------------0.0252--------------
InDex Pharmaceuticals Holding AB0.00-125.26m342.17m6.00--1.15-----0.2314-0.23140.000.54860.00----0.00-32.62-44.83-34.71-49.19---17,889.64---171,599.60----0.0103------2.63------
Magle Chemoswed Holding AB156.62m9.30m351.26m--37.782.3115.552.240.8470.84714.2713.850.58510.43357.68--3.471.264.641.9692.0484.895.941.950.72184.970.2851--10.245.27113.7715.62-2.18--
Vo2 Cap Holding AB (publ)463.51m11.18m352.23m--31.811.646.880.75990.20370.20378.663.961.22--8.77--2.95-4.474.06-6.8030.2024.672.41-3.45--5.760.2007--59.92113.75224.08--50.38--
Alligator Bioscience AB40.59m-216.36m359.84m58.00--7.36--8.87-0.5849-0.58490.10970.07270.1915--4.45753,452.80-102.08-49.02-144.73-55.65-----533.07-994.67---563.720.4679--175.79-8.90-36.45---50.08--
INIFY Laboratories AB0.00-51.06m360.93m----2.85-----1.42-1.420.002.80----------------------------0.00--------------
Orexo AB633.82m-221.57m366.90m122.00--2.77--0.5789-6.34-6.3418.153.760.57881.462.294,949,207.00-20.22-2.02-28.86-3.1783.3584.93-34.94-3.691.72--0.8417--10.50-0.610220.54--71.73--
Lytix Biopharma AS1.41m-60.45m368.63m----3.16--261.62-1.45-1.450.03492.910.0088--0.1969---37.60-58.54-41.51-71.35-----4,290.14-11,603.32----0.00--8,188.245.88-16.56------
Herantis Pharma Oyj0.00-110.25m379.96m-----------0.6758-0.67580.00-0.00360.00-------133.26-84.65-196.74-106.59-----------6.001.01------26.97------
Initiator Pharma A/S0.00-51.63m382.53m----9.76-----1.01-
AlzeCure Pharma AB0.00-54.01m383.67m12.00--7.41-----1.01-
Data as of Jun 05 2023. Currency figures normalised to Exact Therapeutics AS's reporting currency: Norwegian Krone NOK

Institutional shareholders

6.12%Per cent of shares held by top holders
HolderShares% Held
Nordea Investment Management AB (Norway)as of 28 Feb 20231.24m4.15%
Danske Invest Asset Management ASas of 31 May 2023590.75k1.97%
Data from 28 Apr 2023 - 31 May 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.